AR and cancer: Indeed, RB1 inactivation has been linked to cancer initiation and progression (2, 3) and resistance to several targeted therapies, including androgen receptor (AR) antagonists (5–7), ER antagonists (8, 9), CDK4/6 inhibitors (10), and EGFR tyrosine kinase inhibitors (11).